STRATA Skin Sciences, Inc. (SSKN)
| Market Cap | 1.18K -100.0% |
| Revenue (ttm) | 30.70M -8.5% |
| Net Income | -6.26M |
| EPS | -1.35 |
| Shares Out | 5.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,165 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.000001 - 2.2900 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 24, 2026 |
About STRATA Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy sy... [Read more]
Financial Performance
In 2025, STRATA Skin Sciences's revenue was $30.70 million, a decrease of -8.54% compared to the previous year's $33.56 million. Losses were -$6.26 million, -37.92% less than in 2024.
Financial StatementsNews
Strata Skin Sciences appoints Erica Jordan as CEO
Strata Skin Sciences (SSKN) appointed industry veteran Erica Jordan as CEO, effective July 12. Prior to joining Strata, Jordan served as chief commercial officer for Revance Therapeutics. Published fi...
STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase Medical device veteran poised to lead STRATA to market leader...
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vit...
STRATA Skin Sciences Annual report: Q4 2025
STRATA Skin Sciences has published its Q4 2025 annual report on March 26, 2026.
Strata Skin Sciences confirms Nasdaq delisting
Strata Skin Sciences (SSKN) announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of…
STRATA Skin Sciences Confirms Nasdaq Delisting
HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and market...
Strata Skin announces Johns Hopkins Dermatology added XTRAC 308 nm to offerings
STRATA Skin Sciences (SSKN) announces that Johns Hopkins Dermatology has added the XTRAC 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins’ ability...
Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic ...
Strata Skin announces findings from February 2026 review of Excimer laser
Strata Skin Sciences (SSKN) highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the ...
STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis
Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions Growing body of clini...
Laseroptek America Files Counterclaims Alleging Anticompetitive and Unfair Business Practices in Ongoing Litigation with Strata Skin Sciences
LAGUNA HILLS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Laseroptek America Corp. (“Laseroptek America” or “LOA”) today announced that it has filed counterclaims and third-party claims against Strata S...
Strata Skin Sciences showcases XTRAC, TheraclearX at TeraCILAD 2025
STRATA Skin Sciences (SSKN) announces its participation in the 2025 Ibero-Latin American Congress of Dermatology November 19-22, 2025, where it presented its XTRAC excimer laser and TheraclearX acne t...
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin A...
STRATA Skin Sciences Earnings Call Transcript: Q3 2025
Q3 2025 saw strong U.S. recurring revenue and record device billings, offset by a 20% drop in total revenue due to international headwinds. Expanded CPT codes and litigation wins are set to drive future growth, with TheraClearX expanding in Mexico and the U.S.
STRATA Skin Sciences Quarterly report: Q3 2025
STRATA Skin Sciences has published its Q3 2025 quarterly earnings report on November 13, 2025.
STRATA Skin Sciences Earnings release: Q3 2025
STRATA Skin Sciences released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Strata Skin Sciences announces CMS recognition of expanded CPT codes
STRATA Skin Sciences (SSKN) announced that the Centers for Medicare & Medicaid Services, CMS, has issued its CY 2026 Medicare Physician Fee Schedule Final Rule confirming continued reimbursement for e...
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion Higher reimbursement, regulatory ...
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and mark...
STRATA Skin Sciences Proxy statement: Proxy Filing
STRATA Skin Sciences filed a proxy statement on October 30, 2025, providing details for shareholder voting and corporate governance matters.
Strata Skin Sciences announces COFEPRIS clearance of TheraClear in Mexico
STRATA Skin Sciences (SSKN) announced that its TheraClearX acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS, under Device Registration No. 3187E2024S...
Strata Skin Sciences provides update on positioning, litigation
STRATA Skin Sciences (SSKN) provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek, and affiliated entities including The Pinnacle Health...
STRATA Skin Sciences Proxy statement: Proxy Filing
STRATA Skin Sciences filed a proxy statement on October 20, 2025, providing details for shareholder voting and corporate governance matters.
Why Is Strata Skin Sciences Stock (SSKN) Up Today?
Strata Skin Sciences stock rallied alongside positive clinical data related to its excimer laser.
Strata Skin Sciences announces clinical case study on 308-nm excimer laser
STRATA Skin Sciences (SSKN) announces a clinical case study published in Case Reports in Oncology. The study reports the successful use of 308-nm excimer laser to treat a rare and…